Bacterial Vaginosis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Bacterial Vaginosis - Pipeline Review, H1 2019’, provides an overview of the Bacterial Vaginosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis

- The report reviews pipeline therapeutics for Bacterial Vaginosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Bacterial Vaginosis therapeutics and enlists all their major and minor projects

- The report assesses Bacterial Vaginosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Bacterial Vaginosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bacterial Vaginosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bacterial Vaginosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Dare Bioscience Inc

Evofem Biosciences Inc

Melinta Therapeutics Inc

Osel Inc

Pharmiva AB

Starpharma Holdings Ltd

Dare Bioscience Inc

Evofem Biosciences Inc

Melinta Therapeutics Inc

Osel Inc

Pharmiva AB

Starpharma Holdings Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacterial Vaginosis - Overview

Bacterial Vaginosis - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bacterial Vaginosis - Overview

Bacterial Vaginosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bacterial Vaginosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacterial Vaginosis - Companies Involved in Therapeutics Development

Dare Bioscience Inc

Evofem Biosciences Inc

Melinta Therapeutics Inc

Osel Inc

Pharmiva AB

Starpharma Holdings Ltd

Bacterial Vaginosis - Drug Profiles

Amphora - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Bacterial Vaginosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

clindamycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LACTIN-V - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metronidazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

radezolid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

subtilosin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNP-2198 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacterial Vaginosis - Dormant Projects

Bacterial Vaginosis - Discontinued Products

Bacterial Vaginosis - Product Development Milestones

Featured News & Press Releases

Sep 21, 2018: New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine Annual Congress

Jul 09, 2018: VivaGel BV NDA advances to next stage of FDA review

Apr 30, 2018: Starpharma completes US New Drug Application for VivaGel BV

Jan 18, 2018: Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis

Jan 17, 2018: Osel’s LACTIN-V Enters Clinical Study to Improve the Success Rate of IVF in Women With Imbalanced Vaginal Microbiomes

Nov 21, 2017: Starpharma: NDA submission for VivaGel BV in the US

Oct 25, 2017: VivaGel BV granted marketing approval in Australia

Aug 07, 2017: Successful VivaGel Phase 3 results and NDA planned for rBV

Jul 27, 2017: Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA for Prevention of Pregnancy

Jul 04, 2017: VivaGel BV phase 3 results timing and commercialisation

Jun 29, 2017: AMPHORA (L-lactic Acid, citric acid, and potassium bitartrate) Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA

Mar 30, 2017: VivaGel BV phase 3 trials for prevention of BV completed

Jan 12, 2017: VivaGel BV granted QIDP and Fast Track designation by US FDA

Oct 13, 2016: Enrolment complete for Phase 3 VivaGel BV-R program

Aug 17, 2016: Evofem Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bacterial Vaginosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Tables

Number of Products under Development for Bacterial Vaginosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Bacterial Vaginosis - Pipeline by Dare Bioscience Inc, H1 2019

Bacterial Vaginosis - Pipeline by Evofem Biosciences Inc, H1 2019

Bacterial Vaginosis - Pipeline by Melinta Therapeutics Inc, H1 2019

Bacterial Vaginosis - Pipeline by Osel Inc, H1 2019

Bacterial Vaginosis - Pipeline by Pharmiva AB, H1 2019

Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, H1 2019

Bacterial Vaginosis - Dormant Projects, H1 2019

Bacterial Vaginosis - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Bacterial Vaginosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Bacterial Vaginosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports